| 301 |
26389774 | Pacritinib: a new agent for the management of myelofibrosis? | 2015 |
1 |
| 302 |
26433906 | Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group. | 2015 Dec |
1 |
| 303 |
26443624 | Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. | 2015 Nov 26 |
2 |
| 304 |
26552452 | Guidelines for the management of myeloproliferative neoplasms. | 2015 Nov |
1 |
| 305 |
26623653 | The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways. | 2015 |
1 |
| 306 |
26648193 | Practical management of myelofibrosis with ruxolitinib. | 2015 Dec |
1 |
| 307 |
24195509 | INCB018424 induces apoptotic cell death through the suppression of pJAK1 in human colon cancer cells. | 2014 |
1 |
| 308 |
24258498 | A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. | 2014 Feb 15 |
2 |
| 309 |
24292520 | Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. | 2014 Feb |
1 |
| 310 |
24419350 | Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. | 2014 |
1 |
| 311 |
24458439 | Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. | 2014 Apr 3 |
1 |
| 312 |
24501543 | Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. | 2014 |
1 |
| 313 |
24583800 | Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. | 2014 Apr 15 |
1 |
| 314 |
24589536 | Ruxolitinib for the treatment of primary myelofibrosis. | 2014 Mar 15 |
2 |
| 315 |
24754420 | [The place of JAK2 inhibitors in the treatment of myelofibrosis. An amendment to the recommendations for diagnosis and treatment of Ph negative myeloproliferations of the Czech group for Ph- myeloproliferative disorders (CZEMP)]. | 2014 Feb |
1 |
| 316 |
24756798 | Ruxolitinib. | 2014 |
3 |
| 317 |
24763226 | Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis. | 2014 |
1 |
| 318 |
24764577 | JAK2 expression is associated with tumor-infiltrating lymphocytes and improved breast cancer outcomes: implications for evaluating JAK2 inhibitors. | 2014 Apr |
1 |
| 319 |
24766055 | Janus kinase inhibitors for the treatment of myeloproliferative neoplasms. | 2014 Jun |
1 |
| 320 |
24778152 | Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. | 2014 Jun 12 |
1 |
| 321 |
24867113 | Optimizing the management of patients with myelofibrosis. | 2014 Jun |
1 |
| 322 |
24883332 | JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. | 2014 |
1 |
| 323 |
25043171 | The future of JAK inhibition in myelofibrosis and beyond. | 2014 Sep |
1 |
| 324 |
25129481 | Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. | 2014 Sep |
1 |
| 325 |
25180155 | Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. | 2014 |
1 |
| 326 |
25197973 | c-Src binds to the cancer drug Ruxolitinib with an active conformation. | 2014 |
3 |
| 327 |
25390891 | Inhibitors of the interferon response enhance virus replication in vitro. | 2014 |
1 |
| 328 |
25501025 | Definition and management of ruxolitinib treatment failure in myelofibrosis. | 2014 Dec 12 |
1 |
| 329 |
25520049 | Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis? | 2014 Dec |
1 |
| 330 |
25526003 | Drug-associated skin lesions in a patient with myelofibrosis receiving ruxolitinib. | 2014 Oct 15 |
1 |
| 331 |
25696866 | How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms? | 2014 Dec 5 |
1 |
| 332 |
27128228 | Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients. | 2014 Jan |
1 |
| 333 |
22875628 | Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements. | 2013 Mar |
1 |
| 334 |
23307549 | Ruxolitinib: a new treatment option for myelofibrosis. | 2013 Jan |
1 |
| 335 |
23367873 | Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012. | 2013 Apr |
2 |
| 336 |
23391678 | Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis. | 2013 Jan |
2 |
| 337 |
23406773 | Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. | 2013 Apr 15 |
1 |
| 338 |
23656643 | Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. | 2013 May 9 |
1 |
| 339 |
23670175 | Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms. | 2013 Jun |
1 |
| 340 |
23672349 | Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. | 2013 Jul |
1 |
| 341 |
24030211 | Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors. | 2013 Oct |
1 |
| 342 |
24056820 | Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. | 2013 Dec |
2 |
| 343 |
24083419 | Practical management of patients with myelofibrosis receiving ruxolitinib. | 2013 Oct |
1 |
| 344 |
24174625 | Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. | 2013 Dec 12 |
1 |
| 345 |
24238036 | Ruxolitinib for myelofibrosis--an update of its clinical effects. | 2013 Dec |
1 |
| 346 |
24252238 | Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. | 2013 Jan 16 |
1 |
| 347 |
24283870 | Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. | 2013 Oct 22 |
1 |
| 348 |
24290217 | Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms. | 2013 Sep |
1 |
| 349 |
24319228 | JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside. | 2013 |
1 |
| 350 |
24326545 | The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders. | 2013 Dec |
1 |